intellectual property


Summary: Property, such as patents, trademarks, and copyright, that results from creative effort. The Patent and Copyright Clause (Art. 1, Sec. 8, cl. 8) of the United States Constitution provides for promoting the progress of science and useful arts by securing for limited times to authors and inventors, the exclusive right to their respective writings and discoveries. (From Black's Law Dictionary, 5th ed, p1014)

Top Publications

  1. ncbi The role of intellectual property in creating, sharing and repurposing virtual patients
    Gabrielle Campbell
    Association of American Medical Colleges, Washington, DC 20037, USA
    Med Teach 31:709-12. 2009
  2. ncbi Transposon tools: worldwide landscape of intellectual property and technological developments
    Fabien Palazzoli
    UFR des Sciences and Techniques, Universite Francois Rabelais de Tours, GICC, Tours, France
    Genetica 138:285-99. 2010
  3. ncbi Intellectual property. Commons-based strategies and the problems of patents
    Yochai Benkler
    Yale Law School, Yale University, 127 Wall Street, New Haven, CT 06520, USA
    Science 305:1110-1. 2004
  4. ncbi Intellectual property rights. Public sector collaboration for agricultural IP management
    Richard C Atkinson
    University of California, Oakland, CA 94607, USA
    Science 301:174-5. 2003
  5. ncbi An intellectual property sharing initiative in agricultural biotechnology: development of broadly accessible technologies for plant transformation
    Cecilia L Chi-Ham
    Department of Plant Sciences, Public Intellectual Property Resource for Agriculture, University of California, Davis, CA, USA
    Plant Biotechnol J 10:501-10. 2012
  6. ncbi The role of intellectual property rights in treatment access: challenges and solutions
    Ellen 't Hoen
    Medicines Patent Pool Foundation, Geneva, Switzerland
    Curr Opin HIV AIDS 8:70-4. 2013
  7. ncbi Intellectual property issues in genomics
    R S Eisenberg
    University of Michigan Law School, Ann Arbor, MI 48109, USA
    Trends Biotechnol 14:302-7. 1996
  8. pmc Public health, innovation and intellectual property rights: unfinished business
    Tomris Turmen
    Bull World Health Organ 84:338. 2006
  9. ncbi Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spending
    Aaron S Kesselheim
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, in Boston, Massachusetts, USA
    Health Aff (Millwood) 25:1637-47. 2006
  10. ncbi Trade, TRIPS, and pharmaceuticals
    Richard D Smith
    Health Policy Unit, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK
    Lancet 373:684-91. 2009

Detail Information

Publications255 found, 100 shown here

  1. ncbi The role of intellectual property in creating, sharing and repurposing virtual patients
    Gabrielle Campbell
    Association of American Medical Colleges, Washington, DC 20037, USA
    Med Teach 31:709-12. 2009
    ..Unless all intellectual property rights (IPRs) and plans of the authors regarding the VP are confirmed upfront, the ability of the school ..
  2. ncbi Transposon tools: worldwide landscape of intellectual property and technological developments
    Fabien Palazzoli
    UFR des Sciences and Techniques, Universite Francois Rabelais de Tours, GICC, Tours, France
    Genetica 138:285-99. 2010
  3. ncbi Intellectual property. Commons-based strategies and the problems of patents
    Yochai Benkler
    Yale Law School, Yale University, 127 Wall Street, New Haven, CT 06520, USA
    Science 305:1110-1. 2004
  4. ncbi Intellectual property rights. Public sector collaboration for agricultural IP management
    Richard C Atkinson
    University of California, Oakland, CA 94607, USA
    Science 301:174-5. 2003
  5. ncbi An intellectual property sharing initiative in agricultural biotechnology: development of broadly accessible technologies for plant transformation
    Cecilia L Chi-Ham
    Department of Plant Sciences, Public Intellectual Property Resource for Agriculture, University of California, Davis, CA, USA
    Plant Biotechnol J 10:501-10. 2012
    The Public Intellectual Property Resource for Agriculture (PIPRA) was founded in 2004 by the Rockefeller Foundation in response to concerns that public investments in agricultural biotechnology benefiting developing countries were facing ..
  6. ncbi The role of intellectual property rights in treatment access: challenges and solutions
    Ellen 't Hoen
    Medicines Patent Pool Foundation, Geneva, Switzerland
    Curr Opin HIV AIDS 8:70-4. 2013
    The purpose of this study is to review relevant literature published from January 2011 to July 2012 that specifically addresses the impact of intellectual property protection on access to antiretroviral drugs.
  7. ncbi Intellectual property issues in genomics
    R S Eisenberg
    University of Michigan Law School, Ann Arbor, MI 48109, USA
    Trends Biotechnol 14:302-7. 1996
    Controversy over intellectual property rights in the results of large-scale cDNA sequencing raises intriguing questions about the roles of the public and private sectors in genomics research, and about who stands to benefit (and who ..
  8. pmc Public health, innovation and intellectual property rights: unfinished business
    Tomris Turmen
    Bull World Health Organ 84:338. 2006
  9. ncbi Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spending
    Aaron S Kesselheim
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, in Boston, Massachusetts, USA
    Health Aff (Millwood) 25:1637-47. 2006
    ..Generic substitution can reduce costs, but the effects are undercut by extensions of intellectual property (IP) protection, elevated generic prices, and low substitution rates...
  10. ncbi Trade, TRIPS, and pharmaceuticals
    Richard D Smith
    Health Policy Unit, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK
    Lancet 373:684-91. 2009
    The World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) set global minimum standards for the protection of intellectual property, substantially increasing and expanding intellectual-..
  11. ncbi Intellectual property rights and traditional medicine: policy dilemmas at the interface
    Karin Timmermans
    World Health Organization, PO Box 1302, Jakarta 10350, Indonesia
    Soc Sci Med 57:745-56. 2003
    ..It points to possible modifications and at ways to devise new forms of intellectual property ownership that may better suit the needs of those who seek to protect traditional medicine...
  12. ncbi Human-tissue-related inventions: ownership and intellectual property rights in international collaborative research in developing countries
    P A Andanda
    University of Witwatersrand, Private Bag 3, Wits 2050, Johannesburg, South Africa
    J Med Ethics 34:171-9. 2008
    ..The question of intellectual property rights over commercially viable products or procedures that are derived from these samples and the ..
  13. doi Intellectual property and royalty streams in academic departments: myths and realities
    Thomas M Krummel
    Stanford University School of Medicine Department of Surgery, Stanford, Calif, USA
    Surgery 143:183-91. 2008
  14. ncbi Intellectual property. Enhanced: intellectual property landscape of the human genome
    Kyle Jensen
    Department of Chemical Engineering, Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Science 310:239-40. 2005
    ..Unsurprisingly, genes associated with health and disease are more patented than the genome at large. The intellectual property rights for some genes can become highly fragmented between many owners, which suggests that downstream ..
  15. ncbi Intellectual property. University licensing and the Bayh-Dole Act
    Jerry G Thursby
    Department of Economics, Emory University, Atlanta, GA 30306, USA
    Science 301:1052. 2003
  16. ncbi Ethnobotany/ethnopharmacology and mass bioprospecting: issues on intellectual property and benefit-sharing
    D D Soejarto
    PCRPS, College of Pharmacy, University of Illinois at Chicago, 833 S Wood Street, Chicago, IL 60612, USA
    J Ethnopharmacol 100:15-22. 2005 is the Memorandum of Agreement (MOA) that recognizes issues on genetic access, prior informed consent, intellectual property and the sharing of benefits that may arise as a result of the effort...
  17. ncbi Intellectual property and biotechnology: the European debate
    Baruch Brody
    Center for Medical Ethics, Baylor College of Medicine, TX, USA
    Kennedy Inst Ethics J 17:69-110. 2007
  18. ncbi Nano-microbicides: challenges in drug delivery, patient ethics and intellectual property in the war against HIV/AIDS
    Lisa C du Toit
    University of the Witwatersrand, Department of Pharmacy and Pharmacology, Johannesburg, South Africa
    Adv Drug Deliv Rev 62:532-46. 2010
    ..The role of nanotechnology in the antiviral arena and the unique issues facing the generation of intellectual property relating to nano-microbicides in the ongoing global 'tug-of-war' of 'patients versus patents' are also ..
  19. ncbi Access to vaccine technologies in developing countries: Brazil and India
    Julie B Milstien
    University of Maryland School of Medicine, 3 bis rue des Coronilles, Résidence Parc de Clementville Bâtiment C, 34070 Montpellier, France
    Vaccine 25:7610-9. 2007 assess the effects of TRIPS on vaccine technology access in Brazil and India, a good understanding of intellectual property management will be useful...
  20. ncbi The dilemma of intellectual property rights for pharmaceuticals: the tension between ensuring access of the poor to medicines and committing to international agreements
    Jillian Clare Cohen
    Department of Philosophy and Religion, 361 Holmes Hall, Northeastern University, Boston, MA 02155 5000, USA
    Dev World Bioeth 3:27-48. 2003
    ..we provide an overview of how the outcomes of the Uruguay Round affected the application of pharmaceutical intellectual property rights globally...
  21. pmc Nature's medicines: traditional knowledge and intellectual property management. Case studies from the National Institutes of Health (NIH), USA
    Ranjan Gupta
    U S National Institutes of Health NIH Office of Technology Transfer, Rockville, MD 20852, USA
    Curr Drug Discov Technol 2:203-19. 2005
    ..We hope that these discussions and our lessons learned would be helpful to others seeking to develop their own models of cooperation for the benefit of global health...
  22. ncbi Intellectual property and biotechnology: the U.S. internal experience--Part I
    Baruch Brody
    Center for Medical Ethics, Baylor College of Medicine, Houston, TX, USA
    Kennedy Inst Ethics J 16:1-37. 2006
    ..questions were raised about the appropriateness of applying to this area a traditional robust system of intellectual property rights. Despite these hesitations, the U.S. rejected suggested modifications...
  23. ncbi Commodification of the sacred through intellectual property rights
    Darrell A Posey
    Oxford Centre for the Environment, Ethics and Society, Mansfield College, University of Oxford, OX2 6JD, Oxford, UK
    J Ethnopharmacol 83:3-12. 2002
  24. pmc Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand
    S Supakankunti
    Centre for Health Economics, Faculty of Economics, Chulalongkom University, Bangkok 10330, Thailand
    Bull World Health Organ 79:461-70. 2001
    The 1994 World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) established minimum universal standards in all areas of intellectual property...
  25. ncbi Extension of market exclusivity and its impact on the accessibility to essential medicines, and drug expense in Thailand: analysis of the effect of TRIPs-Plus proposal
    Chutima Akaleephan
    International Health Policy Program Thailand, Ministry of Public Health, Tiwanon Road, Muang, Nonthaburi 11000, Thailand
    Health Policy 91:174-82. 2009
    ..In addition, it would foreseeably lead to high and unaffordable medicine prices and inaccessibility to essential medicines...
  26. pmc Scrooge and intellectual property rights
    Joseph E Stiglitz
    BMJ 333:1279-80. 2006
  27. ncbi Intellectual property and biotechnology: the U.S. internal experience--Part II
    Baruch Brody
    Center for Medical Ethics, Baylor College of Medicine, Houston, TX, USA
    Kennedy Inst Ethics J 16:105-28. 2006
    ..of the United States to adequately consider possible modifications in the traditional robust system of intellectual property rights as applied to biotechnology...
  28. pmc Data sharing and intellectual property in a genomic epidemiology network: policies for large-scale research collaboration
    Dave A Chokshi
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, England
    Bull World Health Organ 84:382-7. 2006
    ..Here we consider data-sharing and intellectual property policies for an international research consortium working on the genomic epidemiology of malaria...
  29. pmc How do intellectual property law and international trade agreements affect access to antiretroviral therapy?
    Michael Westerhaus
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, United States
    PLoS Med 3:e332. 2006
  30. ncbi Poverty, health & intellectual property rights with special reference to India
    K Satyanarayana
    Intellectual Property Rights Unit, Indian Council of Medical Research, New Delhi, India
    Indian J Med Res 126:390-406. 2007
    ..In addition, global intellectual property rights (IPR) protection regimes like the Trade Related Intellectual Property Rights (TRIPS) are considered ..
  31. ncbi No agreement reached in talks on access to cheap drugs
    Bebe Loff
    Lancet 360:1951. 2002
  32. ncbi The anti-intellectual effects of intellectual property
    Christopher A Lipinski
    Scientific Advisor, Melior Discovery, 10 Connshire Drive, Waterford, CT 06385 4122, USA
    Curr Opin Chem Biol 10:380-3. 2006
    b>Intellectual property considerations decrease research productivity in subtle and unanticipated ways. Chemical probe exchange between Pharma and academia is hindered by academic IP interests...
  33. pmc Report of the Commission on Intellectual Property Rights, Innovation and Public Health: an industry perspective
    Eric Noehrenberg
    International Federation of Pharmaceutical Manufacturers and Associations, Geneva, Switzerland
    Bull World Health Organ 84:419-20. 2006
  34. ncbi An overview of pharmaceutical cocrystals as intellectual property
    Andrew V Trask
    Jones Day, 222 East 41st Street, New York, New York 10017, USA
    Mol Pharm 4:301-9. 2007
    ..The article provides an outlook on how the developing field of cocrystallization may impact the pharmaceutical intellectual property landscape.
  35. ncbi "Obvious to try": a proper patentability standard in the pharmaceutical arts?
    Andrew V Trask
    Fordham Law Rev 76:2625-68. 2008
  36. ncbi You have an idea, now what?
    Michael Gertner
    Department of Surgery, Stanford University School of Medicine, Stanford, California 94305, USA
    Semin Pediatr Surg 15:302-8. 2006
    ..Often, the most efficient pathway involves an appreciation of many issues, including intellectual property, regulatory pathways, finance, and clinical trial strategies...
  37. ncbi Ethico-legal issues in biomedicine patenting: a patent professional viewpoint
    R Stephen Crespi
    Sci Eng Ethics 11:117-36. 2005
    ..Whereas copyright, trade marks, and other species of Intellectual Property Rights (IPR) are widely acceptable, the patent system evokes criticism from many quarters, especially in ..
  38. ncbi The impact of TRIPS on innovation and exports: a case study of the pharmaceutical industry in India
    Prabodh Malhotra
    Centre for Strategic Economic Studies, Victoria University, Melbourne, Australia
    Indian J Med Ethics 5:61-5. 2008
    Currently, there is a debate on what impact the implementation of the Trade Related Aspects of Intellectual Property Rights (TRIPS) in India would have on its pharmaceutical industry and health care...
  39. ncbi Apomixis technology development-virgin births in farmers' fields?
    Charles Spillane
    Institute of Plant Biology and Zurich Basel Plant Science Center, University of Zurich, Ch 8008 Zurich, Switzerland
    Nat Biotechnol 22:687-91. 2004
    ..Early consideration of issues relating to biosafety and intellectual property (IP) management can facilitate the acceptance and deployment of apomixis technology in agriculture.
  40. doi China steps up US biotech intellectual property land grab
    Mark Ratner
    Nat Biotechnol 26:141-2. 2008
  41. ncbi BioAsia Licensing and Deal-Making Summit-SRI Conference. Life science partnering and investment on the Pacific Rim 2-3 August, 2004, Coronado, CA, USA
    Jing Xu
    BioMinerva Group, 11553 Hadar Drive, San Diego, CA 92126, USA
    IDrugs 7:841-5. 2004
    ..industry was also covered prominently, including assessments of the Chinese market, discussions on intellectual property, regulatory and tax issues, as well as case studies of Sino-US collaborations and technology showcases ..
  42. ncbi Unfair competition under the TRIPS agreement: protection of data submitted for the registration of pharmaceuticals
    Carlos Maria Correa
    University of Buenos Aires, Argentina
    Chic J Int Law 3:69-85. 2002
  43. ncbi Patenting for the research scientist: an update
    R Stephen Crespi
    16 Kenlegh, Bognor Regis, West Sussex, PO21 3TS, UK
    Trends Biotechnol 22:638-42. 2004
    ..Inventors need, however, to be aware of recent patent office guidelines and court decisions if they are to seek useful intellectual property as a basis for technology transfer to industry.
  44. ncbi Biotech in post-TRIPS India
    Shyama V Ramani
    Nat Biotechnol 23:18-9. 2005
  45. ncbi US courts struggle with new patent infringement standards
    Phill Jones
    Nat Biotechnol 22:461-3. 2004
  46. ncbi A level playing field for intellectual property enforcement
    Stephen Carter
    Olswang, London, UK
    Med Device Technol 15:11. 2004
    ..A proposed new Directive creates harmonised rights enforcement across Europe...
  47. ncbi Trade, drugs, and health-care services
    Patrick A Messerlin
    Institut d Etudes Politiques de Paris, 27, rue Saint Guillaume, 75007 Paris, France
    Lancet 365:1198-200. 2005
  48. ncbi Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
    Daniele Dionisio
    Infectious Disease Division, Pistoia Hospital, 51100 Pistoia, Italy
    Curr HIV Res 4:3-20. 2006
    Threats by enforced Intellectual Property (IP) rights to equitable HIV treatment access by poor populations are impending...
  49. ncbi [Industry and pharmaceutical research in Italy. How to make up for lost time]
    Umberto Mortari
    Merck Sharp and Dohme Italia S p A, Roma
    Recenti Prog Med 97:634-9. 2006
    ..incentives for the industrial research; strengthening of the legislative framework for the protection of intellectual property; enhanced dynamism and courage from industry itself, boosted by a constructive networking with the ..
  50. ncbi Intellectual property and patent in stem cell research era
    Sorapop Kiatpongsan
    Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University Rama 4 Rd, Pathumwan, Bangkok 10330, Thailand
    J Med Assoc Thai 89:1984-6. 2006
    ..International patent barriers will be a crucial step to move the whole stem cell research community forward...
  51. ncbi The pharmaceutical industry as a medicines provider
    David Henry
    School of Medical Practice and Population Health, Faculty of Health, University of Newcastle, New South Wales, Australia
    Lancet 360:1590-5. 2002
    ..There is controversy over these claims. Concerns about the harmful effects of the international system of intellectual property rights have led the World Trade Organization to relax the demands placed on least developed countries, and ..
  52. ncbi Pills, patents, and power: state creation of gray markets as a limit on patent rights
    Shubha Ghosh
    Fla J Int Law 14:217-60. 2002
  53. ncbi Gold in the ivory tower: equity rewards of outlicensing
    Mark Edwards
    Recombinant Capital, 2033 North Main Street, Walnut Creek, California 94596, USA
    Nat Biotechnol 24:509-15. 2006
    ..An analysis of life-science initial public offerings from three time periods reveals that the equity share received by universities and their academic researchers has changed over time...
  54. ncbi Big pharma wants you
    George S Mack
    Nat Biotechnol 24:1317-9. 2006
    ..There's another kind of venture capitalist lurking in the corridors of capital...
  55. ncbi Access to tangible research materials in biomedical research: conditions of access and their effect on research
    Ann L Monotti
    Monash University
    J Law Med 14:86-101. 2006
    ..It concludes that the extensive experience and precedent material in the United States provides an immediate resource to help improve access to biological materials in Australian universities...
  56. ncbi Biodiversity, biopiracy and benefits: what allegations of biopiracy tell us about intellectual property
    Chris Hamilton
    London School of Economics and Political Science, United Kingdom
    Dev World Bioeth 6:158-73. 2006
    ..examines the concept of biopiracy, which initially emerged to challenge various aspects of the regime for intellectual property rights (IPR) in living organisms, as well as related aspects pertaining to the ownership and apportioning ..
  57. ncbi Intellectual capital as property
    Amit Sen Gupta
    Delhi Science Forum, D 158, Lower Ground Floor, Saket, New Delhi 110017, India
    Indian J Med Ethics 1:115-6. 2004
  58. ncbi The patentability of medicinal inventions related to personalized medicine in Japan
    Itsuki Shimbo
    Research Priority Committee, RIKEN, 2 1 Hirosawa, Wako Shi, Saitama, 351 0198, Japan
    Nat Biotechnol 23:1367-9. 2005
    ..Several amendments of the examination guidelines for medicinal inventions may be good news for pharmaceutical companies...
  59. ncbi [Intellectual property rights and right of access to medicines]
    G Velasquez
    Département de Coopération technique pour les médicaments essentiels et la médecine traditionnelle, l Organisation mondiale de la santé, Geneve, Suisse
    Med Trop (Mars) 66:526-8. 2006
    The agreement on trade-related aspects of intellectual property rights (trips) was established in 1994 simultaneously with the founding of the world trade organization (wto)...
  60. ncbi The interaction between intellectual property and drug regulatory systems: global perspectives
    Edward A Madden
    Tilleke and Gibbins International Ltd, Tilleke and Gibbins Building, 64 1 Soi Tonson, Ploenchit Road, Bangkok 10330, Thailand
    IDrugs 10:116-20. 2007
    ..To justify developmental and regulatory compliance costs, drug innovators turn to the intellectual property (IP) system to provide a means for securing returns on investment...
  61. ncbi Building a strategy for maximizing intellectual property value
    William A Barrett
    Moore and Van Allen, Durham, North Carolina 27705 4658, USA
    Nat Biotechnol 23:387-9. 2005
  62. ncbi Technology managers do their bit for world health
    Ashley J Stevens
    Nature 435:561. 2005
  63. ncbi The World Health Organization's prequalification program and its potential effect on data exclusivity laws
    David W Childs
    Food Drug Law J 60:79-97. 2005
  64. ncbi Intellectual property. U.S. patent reform begins long journey through Congress
    Eli Kintisch
    Science 308:1725-6. 2005
  65. ncbi Big companies helped by safe harbour ruling
    Simon Frantz
    Nat Rev Drug Discov 4:525-6. 2005
  66. ncbi Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries
    J M Spectar
    Rockefeller College, Princeton University, USA
    Houst J Int Law 24:227-78. 2002
  67. ncbi Access to generic antiretrovirals: inequality, intellectual property law, and international trade agreements
    Arachu Castro
    Department of Social Medicine, Harvard Medical School, 641 Huntington Avenue, Boston, MA 02115, USA
    Cad Saude Publica 23:S85-96. 2007
    ..low- and middle-income countries are currently instituting rules that strengthen changes in domestic intellectual property legislation, often made to conform to the mandates of "free" trade agreements signed with the United ..
  68. ncbi Genetic patent protection in the pharmaceutical and biotechnology industries
    Allen C Nunnally
    Wilmer Cutler Pickering Hale and Dorr LLP, Boston, Massachusetts 02109, USA
    Community Genet 8:209-16. 2005
    ..and biotechnology industries and the critical role the patent regime plays in driving investment in these areas, a clearer picture of the necessity of strong intellectual property rights in the context of genetics will emerge.
  69. ncbi International intellectual property, access to health care, and human rights: South Africa v. United States
    Winston P Nagan
    University of Florida Fredric G Levin College of Law, USA
    Fla J Int Law 14:155-91. 2002
  70. ncbi Andrew Gearing. Interview by Suzanne Berry
    Suzanne Berry
    Trends Biotechnol 20:404-5. 2002
  71. ncbi Transfusion medicine technology transfer: traps to avoid
    Philip Mendes
    Technology Law, Brisbane, Australia
    Transfus Med Rev 16:25-33. 2002
    ..Research organizations including hospitals, universities, and blood banks need to own the intellectual property that they seek to commercialize...
  72. pmc Patents and innovation in cancer therapeutics: lessons from CellPro
    Avital Bar-Shalom
    American Association for the Advancement of Science, Washington, D C, USA
    Milbank Q 80:637-76, iii-iv. 2002
    This article discusses the interaction between intellectual property and cancer treatment. CellPro developed a stem cell separation technology based on research at the Fred Hutchinson Cancer Center...
  73. ncbi Medicine. The need for a global HIV vaccine enterprise
    Richard D Klausner
    Bill and Melinda Gates Foundation, Seattle, WA 98102, USA
    Science 300:2036-9. 2003
  74. ncbi Intellectual property law: a primer for scientists
    William M Brown
    Restoragen, Inc, Lincoln, NE 68524, USA
    Mol Biotechnol 23:213-24. 2003
    b>Intellectual property (IP) is a generic legal term for patents, copyrights, and trademarks, which provide legal rights to protect ideas, the expression of ideas, and the inventors and creators of such ideas...
  75. ncbi Science and the law. Working through the patent problem
    John P Walsh
    Department of Sociology, University of Illinois at Chicago, Chicago, IL 60607 7140, USA
    Science 299:1021. 2003
  76. ncbi Access to affordable HIV/AIDS drugs: the human rights obligations of multinational pharmaceutical corporations
    Lissett Ferreira
    Fordham Law Rev 71:1133-79. 2002
  77. ncbi Patentability and maximum protection of intellectual property in proteomics and genomics
    Richard J Warburg
    Foley and Lardner, 11250 El Camino Real, Suite 200, San Diego, CA 92130, USA
    Pharmacogenomics 4:81-90. 2003
    ..With this setting, we must consider what can be done to best protect this new generation of inventive activity. Moreover, we must consider the possible demise of the drug pipeline should this trend to narrow protection continue...
  78. ncbi On the road to California
    Natalie DeWitt
    Nature 420:A9. 2002
  79. ncbi How can you patent genes?
    Rebecca S Eisenberg
    University of Michigan School of Law
    Am J Bioeth 2:3-11. 2002
    ..The fact that genes are both material molecules and informational systems helps explain the difficulty that the patent system is going to continue to have...
  80. ncbi The role of the private sector in biotechnology: research and development
    Lila Feisee
    Biotechnology Industry Organizations BIO, Washington, DC, USA
    Health Matrix Clevel 12:357-65. 2002
  81. ncbi Intellectual property protection of plant biotechnology inventions
    Konrad A Sechley
    Gowling Lafleur Henderson LLP, Ottawa, Ontario, Canada
    Trends Biotechnol 20:456-61. 2002
    The intellectual property protection of biotechnology-related subject matter is undergoing significant change and several countries have revised their legislation and/or patent practice as a result of challenges from industry and members ..
  82. ncbi USA-Morocco deal may extend drug patents to 30 years
    Khabir Ahmad
    Lancet 362:1904. 2003
  83. ncbi Genes and patent policy: rethinking intellectual property rights
    Lori B Andrews
    Princeton University, USA
    Nat Rev Genet 3:803-8. 2002
    ..In response to these concerns, various policy options, such as litigation, legislation, patent pools and compulsory licensing, are being explored to ensure that gene patents do not impede the practice of medicine and scientific progress...
  84. ncbi Shackling the shoulders of giants. A report on excerpts from the National Academies' Symposium on the Role of Scientific and Technical Data and Information in the Public Domain, Washington, DC, September 5-6, 2002
    John S Gardenier
    Sci Eng Ethics 9:425-34. 2003
    ..and societal capacity for continued technological innovation are threatened by excessive protection of intellectual property. Excessive protection creates disadvantages not only for scientists and inventors but also for educators/..
  85. pmc Ownership of knowledge--the role of patents in pharmaceutical R&D
    Carlos Maria Correa
    Centre of Interdisciplinary Studies of Industrial and Economic Law, University of Buenos Aires, Av Figueroa Alcorta 2263, 1st Floor, 1425 Buenos Aires, Argentina
    Bull World Health Organ 82:784-7; discussion 787-90. 2004
    ..Developing countries should design and implement their patent laws so as to prevent strategic patenting and promote competition and access to medicines...
  86. ncbi Intellectual property protection for plant-related inventions in Europe
    Barbara Fleck
    Boult Wade Tennant, Verulam Gardens, 70 Gray s Inn Road, London WC1X 8BT, UK
    Nat Rev Genet 4:834-8. 2003
    ..But one important aspect is frequently overlooked--the intellectual property protection of plant-related inventions...
  87. ncbi Perusing property rights in DNA
    F Scott Kieff
    Washington University School of Law, St Louis, Missouri 63130, USA
    Adv Genet 50:125-51; discussion 507-10. 2003
  88. ncbi Teaching engineering ethics using role-playing in a culturally diverse student group
    Robert H Prince
    York University, Dept of Physics and Astronomy, Faculty of Science and Engineering, Toronto, Canada M3J 1P3
    Sci Eng Ethics 12:321-6. 2006
    ..conflict of interest, whistle-blowing, sexual harassment, individual rights, privacy, environment, intellectual property, and others...
  89. ncbi Melon fruits: genetic diversity, physiology, and biotechnology features
    Hector G Núñez-Palenius
    Plant Genetic Engineering Department, Guanajuato Campus Center of Research and Advanced Studies Cinvestav IPN, National Polytechnic Institute, Irapuato, Guanajuato, Mexico
    Crit Rev Biotechnol 28:13-55. 2008
    ..This may be a combination of technical or performance factors, intellectual property rights concerns, and, most likely, a lack of public acceptance...
  90. ncbi University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy
    Sara E Crager
    Yale University, USA
    Am J Law Med 35:253-79. 2009
    ..and other biologics need to ensure access not only to patents, knowledge, and materials covered by intellectual property, but must also address the problem of access to materials and know-how that are often proprietary trade ..
  91. ncbi A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations
    Eloan Dos Santos Pinheiro
    Instituto de Quimica, UFRJ, CT Bloco A, Lab 641, Cidade Universitaria, Rio de Janeiro, RJ 21945 970, Brazil
    Antiviral Res 79:143-65. 2008
    ..and Compulsory Licenses (VLs, CLs) through the World Trade Organization's TRIP (Treaty Respecting Intellectual Property) provisions arguably contribute to bringing down access prices...
  92. pmc Impact of gene patents and licensing practices on access to genetic testing for cystic fibrosis
    Subhashini Chandrasekharan
    Center for Public Genomics, Center for Genome Ethics, Law and Policy, Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
    Genet Med 12:S194-211. 2010
    ..Interviews with key researchers and intellectual property managers, a survey of laboratories' prices for cystic fibrosis genetic testing, a review of literature on ..
  93. pmc The Tuskegee Syphilis Experiment: biotechnology and the administrative state
    B Roy
    Department of Psychiatry, Albany Medical College, NY 12208
    J Natl Med Assoc 87:56-67. 1995
    The central issue of the Tuskegee Syphilis Experiment was property: property in the body and intellectual property. Once removed from the body, tissue and body fluids were not legally the property of the Tuskegee subjects...
  94. pmc Science-based health innovation in Uganda: creative strategies for applying research to development
    Sheila Kamunyori
    McLaughlin Rotman Centre for Global Health, at the University Health Network and University of Toronto, MaRS Centre, South Tower, Suite 406, 101 College Street, Toronto, Ontario, M5G 1L7, Canada
    BMC Int Health Hum Rights 10:S5. 2010
    ..Classified as a least developed country, Uganda has opted for exemptions from the TRIPS intellectual property protection regime that include permitting parallel importation and providing for compulsory licenses for ..
  95. ncbi Etanercept Immunex
    R L Yung
    University of Michigan Medical Center, Division of Rheumatology, Ann Arbor 48109 1065, USA
    Curr Opin Investig Drugs 2:216-21. 2001
    ..The agreement reflected the strength of Ares-Serono's intellectual property status [352813]...
  96. pmc Auto-disable syringes for immunization: issues in technology transfer
    J S Lloyd
    World Health Organization, Geneva, Switzerland
    Bull World Health Organ 77:1001-7. 1999
    ..influencing technology transfer, including feasibility, corporate interest, cost, quality assurance, intellectual property considerations, and probable time frames for implementation...
  97. ncbi Population genetics and benefit sharing
    B M Knoppers
    Universite de Montreal, Centre de recherche en droit public, CP 6128, Succursale A, Montreal, Que H3C3J6, Canada
    Community Genet 3:212-4. 2000
    ..The Intellectual Property Committee of HUGO has been active in the controversial area of patenting...
  98. ncbi Predictive DNA testing for glaucoma: reality in 2003
    David A Mackey
    Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, 32 Gisborne Street, East Melbourne, Victoria 3002, Australia
    Ophthalmol Clin North Am 16:639-45. 2003
    ..A further consideration, which may regrettably become important in the future, is that of intellectual property and patent issues pertaining to glaucoma gene discovery...
  99. pmc Driving a decade of change: HIV/AIDS, patents and access to medicines for all
    Ellen t Hoen
    Medicines Patent Pool Initiative, UNITAID Secretariat, Geneva, Switzerland
    J Int AIDS Soc 14:15. 2011 the 2001 World Trade Organization's Doha Declaration on the Agreement on Trade-Related Aspects of Intellectual Property Rights and Public Health...
  100. ncbi Analysis of patents on anti-allergic therapies issued in China from 1988 to 2008
    Shu Zhang
    The First Affiliated Hospital of Nanjing Medical University, Clinical Research Center, Nanjing, Jiangsu 210029, China
    Expert Opin Ther Pat 20:727-37. 2010
    ..However, little is known what anti-allergic products have been patented in China and what the potential drug candidates for patents are in China...
  101. ncbi Development of agriculture biotechnology in Pakistan
    Yusuf Zafar
    Pakistan Atomic Energy Commission, Agriculture and Biotechnology Division, PO Box No 1114, Islamabad, Pakistan
    J AOAC Int 90:1500-7. 2007
    ..Several legislations under the Agreement on Trade-Related Aspects of Intellectual Property Rights have been promulgated in the country...

Research Grants79

  1. Discovery of Small Molecule MBT Domain Antagonists
    STEPHEN VERNON FRYE; Fiscal Year: 2010
    ..research would be made freely available to the academic biology community with no restrictions on use or intellectual property constraints...
  2. New therapeutics for the treatment of Acinetobactor baumannii infections.
    ALLEN BERNARD REITZ; Fiscal Year: 2013
    ..such as topological polar surface area and Log P as well as considerations of our ability to create new intellectual property. Aim 2 involves iterative in vitr biological testing assays to track biochemical and cellular activity ..
  3. Validation of a Novel NF-kB Inhibitor in Inflammatory Bowel Disease
    Anthony Blikslager; Fiscal Year: 2013
    ..TheraLogics, Inc., have been at the forefront of NF??B research and hold intellectual property pertaining to novel NF??B inhibitor peptides including TLX1423...
  4. Fast accurate ultrasensitive in vitro assay to determine BoNT potency &stability
    ARMIN H REITMAIR; Fiscal Year: 2012
    ..Nesher Technologies, Inc. (NTI) has exclusively licensed the intellectual property for a revolutionary quantitative, ultrasensitive and -specific biodetection technology, developed at the ..
  5. Organismal Radioprotection Through Pharmacological Quiescence
    JOHN S CHANT; Fiscal Year: 2010
    ..G-Zero has licensed broad intellectual property surrounding the use of PQ for radioprotection...
  6. Rapid, Highly Multiplexed and Sensitive Blood Test for Drug-resistant Bacteria
    ARMIN H REITMAIR; Fiscal Year: 2010
    ..NTI has licensed the intellectual property for a revolutionary ultrasensitive biodetection technology with exquisite single well multiplexing ..
  7. Development of novel therapies for aging-induced skeletal muscle atrophy.
    SCOTT MATTHEW EBERT; Fiscal Year: 2013
    ..Emmyon, Inc. is in the final stages of negotiation for an exclusive license to this intellectual property. In this phase I SBIR study, Emmyon will begin to develop ursolic acid and the second compound as ..
  8. Establishing a neuroprotection model in the nonhuman primate to support translati
    MATTHEW SWAN LAWRENCE; Fiscal Year: 2013
    ..kinase 1 and caspases, respectively, and to be well tolerated and bioavailable following IVT injection, with combined clinical application encompassed by MEEI intellectual property that we are partnering to advance. !
  9. Humanization of a mouse anti-OX40 monoclonal antibody to treat cancer
    Andrew D Weinberg; Fiscal Year: 2012
    ..for use in cancer clinical trials, has been granted a royalty-bearing, exclusive license for the worldwide Intellectual Property rights to OX40 agonists in cancer immunotherapy from the Sisters of Providence in Oregon...
  10. M tuberculosis Membrane Protein Pharmaceutical Targets
    Timothy A Cross; Fiscal Year: 2013 drug discovery, and while this is beyond the scope of this Program, this team will protect the intellectual property for those who may want to pursue the development of drugs for these membrane protein targets...
  11. Multiplex ALEX-based Test for Protease Activity Profiling in Arthritic Joints
    ARMIN H REITMAIR; Fiscal Year: 2013
    ..NTI has exclusively licensed the intellectual property for ALEX, a revolutionary quantitative, ultrasensitive and -specific biodetection technology, developed at ..
  12. Developing Medications for Nicotine Cessation
    Selena E Bartlett; Fiscal Year: 2011
    ..It is not possible to develop medicines without collaborating with business for intellectual property, licensing and investment as this endeavor needs significant funds and resources...
    STEPHEN VERNON FRYE; Fiscal Year: 2013
    ..The probes developed in the course of this research would be made freely available to the academic community with no restrictions on use or intellectual property constraints.
  14. Hand-Held Infrared Scanner for Early Detection of Melanoma
    Cila Herman; Fiscal Year: 2013
    ..b>Intellectual property generated through these studies is expected to lead to a biotechnology startup company focused on infrared ..
  15. Development of GZ38-1, a Novel Protectant of Chemotherapy-Induced Myelosuppressio
    JAY COPELAND STRUM; Fiscal Year: 2013
    ..G-Zero has licensed from the University of North Carolina the broad intellectual property developed in Dr. Sharpless'lab at UNC surrounding the use of PQ for chemoprotection...
  16. Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis Treatment
    ANDERSON GAWECO; Fiscal Year: 2012
    ..Phase 1 First in Human clinical study start in 2016, an increasing company asset valuation through strong intellectual property position and increasing estate, and potential extension of clinical development in the other high-growth ..
  17. Multiplexed Protein &miRNA Biomarker-based Next-gen Test for Alzheimers Disease
    ARMIN H REITMAIR; Fiscal Year: 2013
    ..Nesher Technologies, Inc. (NTI) has exclusively licensed the intellectual property for a revolutionary, quantitative, ultrasensitive and -specific biodetection technology, developed at the ..
  18. Rapid, Point-of-Care Diagnosis of Neonatal Sepsis
    GREGORY SOMMER; Fiscal Year: 2013
    ..The company has licensed the intellectual property from Sandia for neonatal diagnostic applications...
  19. Bioengineered factor VIII gene therapy for hemophilia A
    H Trent Spencer; Fiscal Year: 2012 the successful clinical application of lentiviral vectors and holder of the largest lentiviral vector intellectual property portfolio...
  20. Clinical Translation of an Anti-Metastatic Antibody for Breast Cancer Therapy
    Kate Rittenhouse-Olson; Fiscal Year: 2013
    ..The long-term objective is to convert the proprietary intellectual property, the mouse monoclonal antibody (McAb) JAA-F11, which targets the pancarcinoma Thomsen-Friedenreich antigen ..
  21. Therapeutic Small Molecule Modulators of G beta gama Signaling
    Val S Goodfellow; Fiscal Year: 2011
    ..were identified from the NCI compound collection and lack drug-like characteristics as well as definitive intellectual property protection, which hampers their commercial development...
  22. Recombinant expression of a biomaterial-targeting BMP-2 containing a peptide tag
    HANNE GRON; Fiscal Year: 2010
    ..This program is also well-timed, with the impending expiration of considerable intellectual property surrounding BMP-2 within the next 2-3 years...
  23. A Novel Method of Generating Hepatitis C Virus-Like Particles using Lentivirus
    Boro Dropulic; Fiscal Year: 2009
    ..Lentigen has exclusive intellectual property in the production of proteins using Lentiviral vector technology...
  24. ALEX for fast ultrasensitive multiplexed detection &quantification of microRNAs
    ARMIN H REITMAIR; Fiscal Year: 2013
    ..Nesher Technologies, Inc. (NTI) has exclusively licensed the intellectual property for a revolutionary quantitative, ultrasensitive and -specific biodetection technology, developed at the ..
  25. Development of CDK4/6 Inhibitors as Novel Renal Protectants
    JAY COPELAND STRUM; Fiscal Year: 2013
    ..G-Zero Therapeutics (GZ) is ready to meet this urgent need for effective renal protectants by leveraging intellectual property surrounding a novel therapeutic approach utilizing proprietary small molecule CDK4/6 inhibitors to induce ..
  26. Definitive Studies For Use Of Galantamine As A Pre-Treatment Countermeasure Again
    BILL BASINGER; Fiscal Year: 2011
    ..Countervail Corporation owns the commercialization rights to the intellectual property and is working as a business partner with the University of Maryland in advancing the drug technology ..
  27. ICBG: "Training, Conservation and Drug Discovery using Panamanian Microorganisms
    William H Gerwick; Fiscal Year: 2013
    ..7) Evolve and maintain the formal contracts between all of the participants in this program to address intellectual property rights, promote equitable sharing of benefits, and to facilitate broad access to the data and results of ..
  28. Genetic Hotspots for Disease Risk
    MARTIN G contact REESE; Fiscal Year: 2010
    ..In addition, any novel variants drawn from this Phase 1 study will be licensable intellectual property, useful both as the basis for future products in our internal pipeline, as well as potentially valuable ..
  29. Multidisciplinary Team-Based Design Education to Create Biomedical Engineering In
    JAY RICHARD GOLDBERG; Fiscal Year: 2013
    ..of and experience with the entire product development process, 4) expanding students'knowledge of intellectual property, product liability, the use of standards in design, regulatory requirements, and other design issues and ..
  30. Chitosan-based Delivery and Immunopotentiation of Cancer Vaccines
    David Zaharoff; Fiscal Year: 2012
    ..Elements of the career development plan included in this proposal include didactic training in intellectual property protection, formation of an advisory board of well funded investigators and enhancing professional ..
  31. Modulation of the Innate Immune System by Fisetin for the Treatment of AD
    PAMELA ANNE MAHER; Fiscal Year: 2013
    ..In addition, the derivatives do not suffer from the intellectual property challenges of the natural product fisetin and are covered under several issued and/or pending patents held ..
  32. UNC Oncology Clinical Translational Research Training Program
    Norman E Sharpless; Fiscal Year: 2013
    ..cancer research in the areas of murine models, novel therapeutics, Phase I trials and commercialization of intellectual property. Dr Thomas Stinchcombe, Associate Professor and Hematology/Oncology fellowship program director, has newly ..
  33. Ultra-Low Background NIR Fluorophores for In Vivo Imaging and Image-Guided Surger
    John V Frangioni; Fiscal Year: 2013
    ..Importantly, we also present an intellectual property strategy that will permit free sharing of optimized NIR fluorophores within the academic community...
  34. OPPC targeting to improve pancreatic cancer treatment
    George C Prendergast; Fiscal Year: 2013
    ..While simple, this compound is a novel structure of matter that represents patentable intellectual property. Under normal glucose and normoxidative conditions (i.e...
  35. Diagnosis, Prognosis and Treatment of hRgr associated Hematopoietic Malignancies
    Angel Pellicer; Fiscal Year: 2012
    ..Finally, we are positioning the program and its intellectual property so that it will be of interest to pharma companies and other institutional investors when we reach ..
  36. Intellectual Property Challenges for the Development of Genomic Diagnostics
    Subhashini Chandrasekharan; Fiscal Year: 2010
    ..Developing such tests poses significant challenges, including mapping a complex intellectual property landscape and navigating potential thickets of existing DNA-sequence patents...
  37. Development of Wnt Pathway Inhibitors for Colorectal Cancer
    Darren Orton; Fiscal Year: 2010
    ..Due to intellectual property issues (SST-024 is off- patent) and concerns about bioavailability, we embarked on a virtual screening ..
  38. Riluzole Prodrugs for Melanoma and ALS
    ALLEN BERNARD REITZ; Fiscal Year: 2013
    ..and for possible consideration for additional indications, continued patent prosecution of the important intellectual property involved, and preparation of 5 kg of cGMP of FCC-311...
  39. A Mini-Cyclotron Facility to Support Cancer Research at the BIDMC/HMS
    John V Frangioni; Fiscal Year: 2010
    ..Due to a complex web of economic, intellectual property, and logistical issues, commercial availability of other useful radiotracers is severely limited and is ..
  40. Structural and Computational Biophysics Training Program
    Leslie B Poole; Fiscal Year: 2013
    ..academic careers, careers in the biotechnology and pharmaceutical industries, as well as careers in the intellectual property arena...
  41. Development of IFN-lambda3 for the Prevention and Treatment of Virus Infection
    Sergei V Kotenko; Fiscal Year: 2013
    ..investigators with the participation of a pharmaceutical company, the team that has necessary expertise, intellectual property and capability to develop and test IFN-?- based therapeutics for biodefense...
  42. A Low Cost, Accurate, and Portable Detection Method for Contaminant Levels in Foo
    Jiahuan Ding; Fiscal Year: 2012
    ..based on patent-pending Si biochemical fin field effect transistor (bio-finFET, similar to nanowire FETs) intellectual property exclusively licensed from The University of Texas at Dallas (UTD)...
  43. Intellectual Property and Access to Noninvasive Prenatal Genetic Testing
    Subhashini Chandrasekharan; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The purpose of this study is to provide empirical data on effects of intellectual property (IP) and commercialization on clinical translation of noninvasive prenatal genetic testing (NIPT) and ..
  44. Molecular Response and Imaging-based Combination Strategies for Optimal PDT
    Tayyaba Hasan; Fiscal Year: 2013 three areas: Core A, through administration, scientific integration, education and career development, intellectual property development, and administration;Core B, through biological models, molecular pathology, and biostatistics;..
  45. Ambulatory_Physiological_Monitor_for_Posttraumatic_Stress_Disorder
    MARK BLY; Fiscal Year: 2013
    ..multiple parameters into a compact wearable device, the device will incorporate sensor and algorithm intellectual property for improved signal to noise ratio...
  46. Small Molecule p75 Neurotrophin Receptor Ligand to Treat Huntington's Disease
    Frank M Longo; Fiscal Year: 2013
    ..Recently, the ligand received FDA approval for phase I clinical testing. Intellectual property for the compound is intact and owned by UNC and UCSF...
  47. A safer urinary catheter design to reduce catheter trauma and infections
    BUZZY BONNEAU; Fiscal Year: 2013
    ..catheter placement (2) prototype a cost equivalent safer urethral catheter based upon our licensed intellectual property;(3) test these prototypes in ex vivo and animal models to further hone the parameters of our catheter ..
  48. Early Screening of Breast Lesion Trial (Phase III Pivotal)
    David A Benaron; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): This amended trial (prior score 194) combines the experience and intellectual property of 3 NCI-funded Optical Breast Cancer groups, and proposes an early-detection cancer trial...
  49. Hybernia Safety Catheter for Neuroprotection via Selective Hypothermia
    JOHN MARTIN PILE-SPELLMAN; Fiscal Year: 2011
    ..Hybernia Medical, LLC is developing a device based on intellectual property assigned to Columbia University (USPTO 20090018504) that addresses these issues by inducing safe, rapid, ..
  50. Low Cost and Portable Retinal Imager
    Abhishek Rege; Fiscal Year: 2012
    ..We have developed intellectual property central to the realization of such a device through two innovations: firstly, the extraction of retinal ..
  51. Targeted Gene Expression from NL63 Vaccine Vectors
    Amy C Sims; Fiscal Year: 2010
    ..vaccine vector, especially for use in the developing world, which has poor access to vaccines or intellectual property dedicated toward improving human health...
  52. Computational system to predict novel genetic disease associations
    MARK DOUGLAS YANDELL; Fiscal Year: 2010
    ..In addition, any novel variants drawn from this Phase II study will be licensable and exploitable intellectual property, useful both as the basis for future products in our internal pipeline, as well as potentially valuable ..
  53. Enhancing Faculty Recruitment in Nanoscale Sciences for Biomedical Research
    Yogesh K Vohra; Fiscal Year: 2010
    ..The intellectual property generated by the nanotechnology research efforts of these new faculty hires will further lead to new ..
  54. International Assessments of Patenting in Genetics
    Philip Pardey; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Evolving intellectual property (IP) policies of governments and organizations are impacting biotechnology sectors and access to genetic materials for development of pharmaceuticals...
    Sukhraaj Basati; Fiscal Year: 2012
    ..Systems Science Inc. will capitalize on existing intellectual property on a ventricular volume sensor developed by the investigators at UIC to develop a novel medical device by ..
  56. Developing Innovative Interdisciplinary Biomedical Engineering Programs in Africa
    Robert L Murphy; Fiscal Year: 2013
    ..programs in biomedical engineering starting with needs assessment and product design, continuing to validation, intellectual property protection, production and finally to marketing and distribution in the LMICs.
  57. Preclinical Medications Screening in Genetic Models of Alcoholism
    Richard Bell; Fiscal Year: 2011
    ..We will use contractual mechanisms having intellectual property conditions favorable to compound providers...
  58. Hypericum extracts as potential anti-relapse medications in alcoholism
    John M Littleton; Fiscal Year: 2010
    ..The resulting stronger Intellectual Property (compared to known active H perforatum extracts) will make these more commercially attractive as ..
  59. Center for Public Genomics 2.0
    Robert Mullan Cook-Deegan; Fiscal Year: 2013
    ..for Public Genomics (CpG) was established in 2004 to study two important aspects of genomics research: intellectual property (IP), and norms and practices of sharing data and materials...
  60. Vanderbilt-Zambia Network for Innovation in Global Health Technologies
    David W Wright; Fiscal Year: 2013
    ..on topics such as innovative technologies, engineering management, biomedical informatics, and intellectual property. VZNIGHT will establish a network for innovation that develops an ongoing pipeline of technologies and ..
  61. Neuronanomedicine
    Howard E Gendelman; Fiscal Year: 2013 an open forum discussion that will include, but is not limited to, bioethics, safety an toxicity, intellectual property, and product commercialization...
  62. Structure-Activity Relationship of CM101 Tumor antiangiogenic agent with its lect
    BETTY CHOURONG ZHU; Fiscal Year: 2012
    ..More recent intellectual property for CM101 purification and the HP59 receptor now protects products through 2026-2028...
  63. Novel accelerated in vitro breeding for phytoremediation
    MIHALY CZAKO; Fiscal Year: 2007
    ..plants for nurseries and remediation businesses, with licensing and tracking mechanisms for protecting intellectual property. This project is built on the successful demonstration of the feasibility of our novel technology for in ..
  64. Studies of the Flora and Predator Bacteria of Jordan
    NICHOLAS OBERLIES; Fiscal Year: 2004
    ..b>Intellectual property rights and consideration of the People of Jordan have been agreed to in principle and plans for ..
  65. A High Accuracy Point-of-Care Chlamydia trachomatis Test
    Michael Helms; Fiscal Year: 2004
    ..Furthermore the novel aspects of the test system are expected to result in significant intellectual property rights for the company.
  66. Novel Glycosylated Delta Opioid Receptor Agonists for Chronic Inflammatory Pain
    KIMBERLEY GANNON; Fiscal Year: 2009
    ..We will generate additional intellectual property for BBI and identify an early developmental drug candidate from this work that subsequently will be ..
  67. Detection of Ethanol in Human Breath: Mini-GC Use and Exhaled Breath Condensate
    Richard Melker; Fiscal Year: 2007
    ..of the investigators are to develop breath-based detection technology to enable medical diagnostics as sheltered by intellectual property licensed from the University of Florida. [unreadable] [unreadable] [unreadable] [unreadable]
    Mildred Cho; Fiscal Year: 2002
    ..On the one hand, intellectual property practices in biotechnology may provide important incentives for research that leads to innovations in ..
  69. Pulsus Paradoxus Monitor
    Gregory Jay; Fiscal Year: 2005
    ..This Phase 1 effort will result in a refined PP monitor, for which we have a strong intellectual property position, and clinically relevant (validated) PP thresholds, which future asthma management guidelines ..
  70. ELIA Tactile Label Maker
    ANDREW CHEPAITIS; Fiscal Year: 2009
    ..the end product (rather than coming up with their own solutions), but it raises concerns in terms of intellectual property, sourcing appropriate equipment suppliers, and reverse engineering materials as needed...
  71. Novel Inhibitors for the Treatment of Highly Drug-Resistant Chronic Myelogenous
    GERARD HOUSEY; Fiscal Year: 2009
    ..The proposal provides the unique opportunity to further develop and commercialize key intellectual property and technology originally created by NIH-supported scientists at the University of California at Los ..
  72. US-China-Japan Research Consortium on Herbal Medicines
    David Eisenberg; Fiscal Year: 2004
    ..They will negotiate a formal collaboration agreement which satisfactorily addresses issues of intellectual property, royalty sharing, publication procedures and shared access to NIH resources...
  73. A Novel Neuroprotective Approach for Ischemia
    Zhi Gang Jiang; Fiscal Year: 2007
    ..Panacea Pharmaceuticals, Inc. has licensed the used of this compound and maintains intellectual property rights for its use in neuroprotective therapy...
  74. Parkinson's Disease Gene Therapy Study Group
    Howard Federoff; Fiscal Year: 2006
    ..Lowenstein), Human Subjects/Clinical Assessment (Chair: Dr. Kurlan), Bioethics (Chair: Ms. Greenlaw), Intellectual Property (Chair: Ms. Hunter) and Biostatistics Modules (Chair: Dr. Oakes)...
  75. Sharing Research Tools: The Mouse as a Paradigm
    DAVID EINHORN; Fiscal Year: 2007
    ..has so often been at the epicenter of tension between the ethos of sharing and the commercialization of intellectual property. The "mouse wars" over the p53 knockout mouse, the first patented transgenic mouse (the "Harvard Mouse"), ..
  76. Spinal Fusion Using Adipose Derived Adult Stem Cells
    Jeffrey Gimble; Fiscal Year: 2005
    ..Cognate Therapeutics holds unique intellectual property and expertise in the isolation, culture, and differentiation of adult stem cells from subcutaneous adipose ..
  77. Int'l Center for Indigenous Phytotherapy Studies--TICIPS
    William Folk; Fiscal Year: 2004
    ..of research with human subjects and animal subjects, financial disclosure, conflict of interest and intellectual property rights...
    JINSEONG KIM; Fiscal Year: 2003
    ..S. Lynntech is well positioned to commercialize this technology, having secured intellectual property covering many aspects of the invention...
  79. Biodiversity and Drug Discovery in the Phillipines
    Michael Kron; Fiscal Year: 2004
    ..First, a broadly applicable intellectual property and commercial research agreement (CRA) will be forged in accordance with EO245, acceptable to the ..